Latest 4 stories · newest Jul 20, 2026
NeoGenomics has resolved a civil settlement with the DOJ regarding a voluntary disclosure from 2021, agreeing to pay $9.8 million plus interest. This resolution allows the company to proceed with its strategic vision amidst managing a legacy matter.
NeoGenomics appointed Carolyn Starrett to its Board of Directors. Her experience in oncology data and AI strengthens the company's leadership for precision medicine growth.
NeoGenomics Inc. has issued convertible senior notes due 2032 with a 0.75% coupon rate, with U.S. Bank Trust Company serving as trustee. This debt offering provides the company with additional capital for operations and strategic initiatives.
NeoGenomics announced pricing of $275 million in 0.75% convertible senior notes maturing July 1, 2032, with an additional $41.25 million option for underwriters. The notes carry an initial conversion price of $14.16 per share, representing a 35% premium to the June 16 closing price, providing the co…
The same NEO feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/NEO/newsSTART FREE